AdaptHealth Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by AdaptHealth Corp. on December 21, 2023. The report addresses corporate governance changes, specifically the extension of the tenure of the Interim Chief Executive Officer.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation:
- Interim CEO Base Salary: $262,500 per month.
- Restricted Stock Units (RSUs): Grant value of $175,000, effective January 1, 2024, vesting on the Transition Date.
Material Changes
The primary material change is the extension of Richard Barasch's term as Interim Chief Executive Officer. Previously set to end on December 31, 2023, his term has been extended to February 29, 2024 (the "Transition Date"). This change was formalized via the "Interim CEO Third Extension Letter" dated December 21, 2023.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, market outlook, or discussion of general business risks. The document focuses solely on the terms of the executive employment agreement. The vesting of the RSU grant is contingent upon Mr. Barasch's continued service through the Transition Date.
Investor Verification Checklist
- Verify the exact terms of the "Interim CEO Third Extension Letter" attached as Exhibit 10.1.
- Confirm the status of the search for a permanent CEO given the extension of the interim role.
- Review the company's most recent 10-K or 10-Q for comprehensive financial performance data not included in this 8-K.